VYNE Therapeutics (VYNE) EBT Margin (2017 - 2026)
VYNE Therapeutics (VYNE) posted EBT Margin of 4168.6% for Q1 2026, up 27.46% on a QoQ basis from 5747.0% in Q2 2025, and up 13290.0% year-over-year from N/an in Q1 2025.
VYNE Therapeutics (VYNE) EBT Margin (2017 - 2026) Analysis & Trends
VYNE Therapeutics' EBT Margin history runs 10 years deep, the most recent figure standing at 4168.6% for Q1 2026.
- Quarterly EBT Margin rose 13290.0% year-over-year to 4168.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6384.86% (up 61929.0% YoY) and the FY2025 annual result came in at 4689.82%, up 327078.0% from the prior year.
- EBT Margin was 4168.6% for Q1 2026 at VYNE Therapeutics, up from 5747.0% in the prior quarter.
- Across five years, EBT Margin topped out at 4168.6% in Q1 2026 and bottomed at 26717.24% in Q4 2022.
- A 5-year average of 8164.62% and a median of 5747.0% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin plunged 2348647 bps — and 2023, when it surged 1862250 bps.
- VYNE Therapeutics' EBT Margin stood at 26717.24% in 2022, then surged by 70 bps to 8094.74% in 2023, then slumped by 79 bps to 14469.88% in 2024, then soared by 60 bps to 5747.0% in 2025, then increased by 27 bps to 4168.6% in 2026.
- Business Quant data shows VYNE's EBT Margin at 4168.6% in Q1 2026, 5747.0% in Q2 2025, and 4301.5% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -4,168.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,168.60% |
| Jun 30, 2025 | -5,747.00% |
| Mar 31, 2025 | -4,301.50% |
| Dec 31, 2024 | -14,469.88% |
| Sep 30, 2024 | -10,047.11% |
| Jun 30, 2024 | -4,744.95% |
| Mar 31, 2024 | -6,241.00% |
| Dec 31, 2023 | -8,094.74% |
| Sep 30, 2023 | -5,325.44% |
| Jun 30, 2023 | -10,038.00% |
| Mar 31, 2023 | -5,612.00% |
| Dec 31, 2022 | -26,717.24% |
| Sep 30, 2022 | -5,541.92% |
| Jun 30, 2022 | -6,535.71% |
| Mar 31, 2022 | -4,884.27% |
| Dec 31, 2021 | -3,230.77% |
| Sep 30, 2021 | -10,733.83% |
| Jun 30, 2021 | -3,622.03% |
| Mar 31, 2021 | -4,728.70% |
| Dec 31, 2020 | -540.85% |